Skip to main content
logo
Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.500
+0.200 (4.65%)
Mar 31, 2026, 4:00 PM EDT - Market closed

Arbutus Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
14.086.1718.1439.0210.99
Revenue Growth (YoY)
128.21%-65.98%-53.51%255.11%58.92%
Gross Profit
14.086.1718.1439.0210.99
Selling, General & Admin
15.8922.1122.4817.8317.14
Research & Development
25.2454.0473.784.4165.5
Other Operating Expenses
11.116.350.072.231.87
Total Operating Expenses
52.2482.4996.24104.4884.51
Operating Income
-38.16-76.32-78.1-65.46-73.52
Interest Income
4.076.595.692.190.13
Interest Expense
-0.1-0.14-0.46-1.73-2.86
Other Non-Operating Income (Expense)
0.69-0.050.03-0.020.01
Total Non-Operating Income (Expense)
4.666.45.250.44-2.73
Pretax Income
-33.5-69.92-72.85-65.01-76.25
Provision for Income Taxes
----4.44-
Net Income
-33.5-69.92-72.85-69.46-88.39
Net Income Attributable to Preferred Dividends
----12.14
Net Income to Common
-33.5-69.92-72.85-69.46-88.39
Shares Outstanding (Basic)
192186166151106
Shares Outstanding (Diluted)
192186166151106
Shares Change (YoY)
3.23%11.84%9.95%42.07%40.10%
EPS (Basic)
-0.17-0.38-0.44-0.46-0.83
EPS (Diluted)
-0.17-0.38-0.44-0.46-0.83
Free Cash Flow
-39.64-65.03-86.94-35.87-68.34
Free Cash Flow Per Share
-0.21-0.35-0.52-0.24-0.64
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-270.96%-1236.74%-430.53%-167.75%-669.11%
Profit Margin
-237.88%-1133.04%-401.57%-178.01%-693.91%
FCF Margin
-281.45%-1053.83%-479.27%-91.92%-621.96%
EBITDA
-37.8-74.94-76.7-64.03-71.77
EBITDA Margin
-268.39%-1214.37%-422.79%-164.10%-653.16%
EBIT
-38.16-76.32-78.1-65.46-73.52
EBIT Margin
-270.96%-1236.74%-430.53%-167.75%-669.11%
Effective Tax Rate
0.00%0.00%0.00%6.84%0.00%
Updated Mar 23, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q